FDA analysis of 40-years of antibacterial development: Dheman et al.
Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), Just out in CID is a paper in which FDA analyzes trends in
30 June 2020 No Comments
R&D Insight
WHO Bacterial Priority Pathogen List (PPL): 2024 update
Dear All, WHO have just released a 2024 update to their 2017 (bacterial) Priority Pathogen List (PPL)! Here are the links you need: The WHO
18 May 2024 No Comments
Antibacterial R&D is very hard! Two great pipeline reviews + an Industry-level view
Dear All (and with thanks to Stephan Harbarth for co-authoring this newsletter), A new review by Ursula Theuretzbacher and colleagues from GARDP provides an opportunity
4 April 2025 No Comments
AMR in India: A possible global future unless we act now!
Dear All, On 26 Nov 2026, the Antimicrobial Resistance Surveillance & Research Initiative (AMRSRN) of the Indian Council on Medical Research (ICMR) released its report on
2 December 2025 No Comments
Leaving the lab: The decline in AMR R&D professionals
Dear All, The AMR Industry Alliance has today released a fascinating and disturbing report. Entitled “Leaving the Lab: Tracking the Decline in AMR R&D Professionals”
8 February 2024 No Comments
FDA RFPs: Susceptibility breakpoints and external controls for invasive fungal infections
Dear All, I just today learned that FDA has posted two antimicrobial resistance-related (AMR-related) FY 2026 funding opportunities. The titles for the RFPs are very
5 February 2026 No Comments
Manufacturing underpins both access and stewardship: Cefiderocol as a case study
Update: There is a 14 April 2025 follow-up to this newsletter. Dear All, Prompted by an excellent talk by GARDP’s Jennifer Cohn at last week’s
25 September 2023 No Comments
Manufacturing underpins access in LMICs: An update on cefiderocol
Dear All, No one is safe until we’re all safe! In the 7 April 2025 newsletter on antibiotic access (“UNSLAP: You reach for the antibiotic …
14 April 2025 No Comments
Antibiotic supply chains: Challenges & Opportunities
Dear All, In a report entitled Understanding the Antibiotic Manufacturing Ecosystem: A view of global supply chains, pressure points, and implications for antimicrobial resistance response, the
4 May 2022 No Comments
De-risking vaccine development: Insights spanning decades of experience
Dear All (with thanks to Vega Masignani for co-authoring this newsletter), While the work needed to create new antibacterial agents is the primary topic of
21 September 2025 No Comments